TrialESMO open2026

Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.

G K Abou-Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.